TickerFacts.

Company research / RXST

RxSight, Inc. (RXST)

Build a valuation ↗↓ Download CSV

CIK 0001111485 · Nasdaq · Ophthalmic Goods

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, RxSight, Inc. reported revenue of $134.48M. Revenue fell 3.9% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $121.08M.

Key ratios (year ended 2025-12-31)

76.6%
Gross margin
-35.8%
Operating margin
-29.0%
Net margin
-14.1%
Return on year-end equity
-3.9%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-09-16

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Revenue$121.08M$134.48M$139.93M$89.08M$49.01M$22.59M$14.68M
Cost of Revenue$28.71M$31.47M$40.98M$35.31M$27.68M$18.08M$12.97M
Gross Profit$92.38M$103.01M$98.94M$53.77M$21.33M$4.52M$1.71M
R&D Expense$36.67M$38.55M$34.37M$29.05M$25.98M$24.50M$21.93M
Operating Income-$55.11M-$48.19M-$36.86M-$50.09M-$63.32M-$52.79M-$35.41M
Depreciation & Amortization$3.54M$3.27M$3.58M$4.08M$3.88M$3.98M$3.85M
EBITDA-$51.58M-$44.92M-$33.28M-$46.01M-$59.43M-$48.81M-$31.56M
Net Income-$46.95M-$38.94M-$27.45M-$48.61M-$66.76M-$48.69M$27.57M
EPS (Diluted)n/a-$0.95-$0.71-$1.41-$2.41-$3.57$0.15
Total Assets$352.70M$311.81M$318.56M$182.55M$150.16M$192.72M$100.68M
Total Liabilities$89.36M$36.13M$37.33M$22.19M$60.26M$54.48M$44.91M
Long-Term Debtn/an/an/a$0$40.17M$39.76M$24.40M
Shareholders' Equity$263.34M$275.68M$281.24M$160.36M$89.90M$138.24M-$430.59M
Cash & Equivalents$13.35M$19.95M$16.71M$9.69M$11.83M$24.36M$13.99M
Operating Cash Flow-$22.73M-$15.51M-$16.95M-$41.59M-$58.85M-$44.71M-$35.20M
Capital Expenditures$4.43M$3.83M$5.44M$4.81M$2.39M$1.94M$2.54M
Free Cash Flow-$27.16M-$19.34M-$22.39M-$46.41M-$61.24M-$46.65M-$37.74M
Shares Outstanding41.59M41.24M40.43M36.14M28.27M27.37Mn/a
Weighted Average Diluted Sharesn/a40.85M38.87M34.46M27.66M13.63M5.53M
EPS (Basic)n/a-$0.95-$0.71-$1.41-$2.41-$3.57$0.91

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView